The independent university lab had neither a Nocturne nor Kioo logo on the testing-room door. That was the point.
Four coded vials sat on a tray: the old Calm-X comparator from Bibi Tunu, current held Calm-X, a market wellness sample obtained through a separate route, and a K-17 reference. Zawadi sealed the identity key before testing began.
“You want to know which one is guilty,” Dr. Achieng said.
“I want a measurable mechanism,” Leila replied.
“Better.”
The first assay compared carrier profiles and the sensitizer marker relevant to their world's nocturnal-change biology. Sample B showed a markedly higher sensitizer signal than sample A. Sample C overlapped with B but was not identical. The K-17 reference reduced the marker in the controlled reaction.
Before unblinding, Achieng made them write what those results meant without product names.
“B has the higher sensitizer marker,” Leila said.
“Yes.”
“C resembles it.”
“Overlap, not identity.”
“K-17 reduces the pathway.”
“In this assay. That does not guarantee every patient responds the same way.”
The codes were opened. A was old formula. B was current held formula. C was the wellness sample. D was K-17.
“This is the mechanism,” Leila said.
“A mechanism candidate,” Achieng corrected. “We have a measurable formulation difference and a result compatible with the hypothesis. We have not proved Nocturne created the syndrome or that every episode comes from the new formula.”
They reran the assay on a second aliquot with another technician. The trend held. Achieng also tested whether recorded storage conditions could reasonably explain the gap. They could not account for the observed difference, though the report kept the limitation.
Zawadi requested additional lots outside the held group so the review would not cherry-pick only the samples that made the strongest story.
“A good lab does not win cases,” Achieng said. “It makes the case smaller than your fantasy and larger than someone else's denial.”
The Board then provided the technical change packet from Nocturne. Leila organized it by date, not motive. One internal note recorded a repeated-exposure sensitization signal. A later review classified it as non-material pending study. Then came the expansion schedule.
“Can we call it a warning?” Leila asked.
“A safety signal requiring attention,” Achieng said. “Do not call it confirmed harm.”
Media headlines were already claiming the lab had proved Nocturne made people sick. Zawadi rejected the wording.
Their own draft stated: the new formulation carried a higher sensitizer marker than a verified old comparator; adverse events under review showed a compatible pattern; causation beyond those bounds was not established.
A legal officer wanted the phrase dangerous new formulation. Achieng refused. “Dangerous for whom, at what exposure, with what denominator?”
The whiteboard separated three questions: quality difference, clinical association, corporate reporting chronology. None could substitute for the others.
At the end of the packet Leila found the date of the sensitization signal and the date of expansion authorization.
Zawadi verified the versions and recipients.
The dates were six weeks apart.
The lab team also kept the wellness sample in a separate evidentiary lane. Its related profile was important, but its origin was not yet verified enough to claim that the camp had used the same formulation. Achieng added that limitation in bold because the public narrative was already moving faster than the chain of custody.
Zawadi required samples from unaffected lots in the next round. A result that weakened the Board's theory would still be useful. Leila agreed, even though certainty would have been emotionally easier. The purpose of the test was not to reward suspicion; it was to narrow what could honestly be said.
Before leaving, Leila signed the bounded conclusion herself. Doing so meant she would have to defend not only the concerning result but every limitation written beside it. That was preferable to a stronger sentence the evidence could not carry.
The sensitization warning had been recorded six weeks before expansion.